$ONC

Wu Xiaobin sold $400K of ONC

Wu Xiaobin (President and COO) sold 1,484 shares of BeOne Medicines Ltd. (ONC) at an average of $269.37 ($269.33–$270.55, $0.40M total) across 2 trades on 2026-06-08.

Original reporting
SEC EDGAR · Wu Xiaobin
Published Jun 10, 2026, 9:23 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 10, 2026, 9:28 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ONC
Neutral
medium confidence
Mentioned
$ONC
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ONCNeutralLow
01

Why it matters

Traders may monitor for clustering of insider sales or follow-on disclosures, but this single transaction is unlikely to reset valuation without accompanying operational/regulatory catalysts.

02

Market read

A modest insider sale was newly disclosed; it may cause brief sentiment noise but lacks fundamental substance in the text.

03

What to watch

The filing shows the executive ended with 0 shares, but the article provides no context on compensation, option exercises, or prior holdings beyond the post-transaction balance.

Relevance 4/10Novelty 8/10Timing: Filed 2026-06-10; sale executed 2026-06-08

Background

The article is a primary SEC Form 4 disclosure reporting an officer’s open-market sale of ONC shares.

Company-level read

Ticker impact

$ONCNeutralMedium confidence
Context

BeOne Medicines (ONC) disclosed an insider open-market sale by President/COO Wu Xiaobin of 1,484 shares (~$399.7K) on 2026-06-08 via Form 4.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and should fade unless followed by additional insider selling or fundamental news.

Evidence & confidence

Form 4 insider sales are primary-source but typically have low predictive power; the transaction is moderate (~$0.4M) and lacks a stated 10b5-1 plan, which can add marginal interpretive risk.

Market effects

No sector read-across; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider sales often reflect diversification, taxes, or pre-planned liquidity needs; absence of a stated 10b5-1 plan doesn’t necessarily imply negative fundamentals.

Key entities

  • BeOne Medicines Ltd.

    Company whose shares were sold by an insider (Form 4).

  • Wu Xiaobin

    President and COO who sold 1,484 ONC shares on 2026-06-08.

Related articles

$ONCHigh

BeOne Medicines Ltd. (ONC): Results of Operations and Financial Condition

BeOne Medicines Ltd. (ONC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q22026earningsr.htm EX-99.1 Document Exhibit 99.1 BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates • Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year • BRUKINSA (zanubruti

$CRCLMed

Here Are Monday’s Best Wall Street Analyst Research Calls: Atmos Energy, Best Buy, Biogen, Capital One, Costco, Disney, Papa John’s International, Shopify, and More

The article lists Monday analyst calls and market moves. It highlights SK hynix’s Nasdaq debut, up about 12.8% to $168.01 after raising nearly $26.5B. It cites upgrades including BIIB to Buy at $235, COF to Buy at $229, and SHOP to Buy at $160, plus downgrades like BBY to Hold. Circle (CRCL) rose ~15% on OCC approval.

$ONCMed

BeOne Medicines (ONC): Citizens Sees an Inflection Point in Its Cancer Pipeline

Citizens kept a “Market Outperform” rating and $396 price target on BeOne Medicines (NASDAQ:ONC) after the company presented tumor clinical data at ASCO 2026. Citizens highlighted three pipeline programs: BGB-43395 (HR+/HER2- metastatic breast cancer), BG-C9074 (ovarian cancer maintenance), and BGB-B2033 (liver cancer). The target was based on discounted earnings and revenue multiples, with Citizens citing $4.85 billion cash and 88% gross margins.